Gilead Sciences News

Gilead Sciences Inc. said Thursday an advisory committee has recommended U.S. approval of the biotechnology company's inhalable cystic fibrosis treatment candidate.

Gilead Sciences said darusentan, the company's experimental drug to treat resistant hypertension, failed in a late-stage clinical trial.

FOSTER CITY, California-- --Gilead Sciences, Inc. ha anunciado que DAR-312 , un ensayo clinico de Fase III que evalua a darusentan, el antagonista rece... VANCOUVER, British Columbia-- --With less than 60 days to go until the Opening Ceremony for the 2010 Winter Games, Aggreko, the global leader in temporary power generation, temperature c...

Gilead Sciences, Inc. has announced that their high blood pressure treatment drug candidate, Darusentan has failed a drug trial.

Gilead Sciences, Inc. today announced that DAR-312 , a Phase III clinical trial evaluating darusentan, the companya s endothelin receptor antagonist for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure and diastolic blood pressure ...

Gilead Sciences, Inc. announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration has recommended that aztreonam for inhalation solution be approved for the treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis .

FOSTER CITY, Calif.-- --Gilead Sciences, Inc. today announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration has recommend... PORTLAND, Ore.-- --Pacific Seafood, a family-owned seafood company based in Portland, Ore., was honored at The Portland Business Journal's fifth annual Oregon's Most Admired...

A ''patent pool'' could get life-saving drugs to poor folks in Africa. Some drug makers are resisting.

Gilead Sciences Inc. said Thursday an advisory committee has recommended U.S. approval of the biotechnology company's inhalable cystic fibrosis treatment candidate.

The design and analysis of two clinical studies of Gilead Sciences ' late-stage cystic fibrosis treatment may be skewed in the drug's favor, Food and Drug Administration staff said.

The Planning Commission will consider a proposed major expansion of Gilead Sciences' corporate campus at a meeting tonight and make a series of recommendations to the City Council.

Huge numbers of nonprofits exist that are devoted to caring, educating and treating patients diagnosed with HIV and other life threatening diseases.

Gilead Sciences, Inc. cordially invites you to attend the Beyond the Diagnosis community based theater performance in Harlem, NY.

Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced the appointment of Howie Rosen to the company's Board of Directors.

Gilead Sciences, Inc. and GlaxoSmithKline today announced a licensing agreement to commercialize Viread for the treatment of chronic hepatitis B infection in adults in five countries in Asia.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, biotech giant Gilead Sciences has earned a coveted five-star ranking .

David Gardner called it. Hea TMs up 1,334%! See what Davida TMs recommending that you buy NEXT.

We have a large pool of in-house financial professionals, a wide array of research platforms and a dedicated team that combined would bring enhanced knowledge and first-hand information that would help you manage your understanding of the market.

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/30/09, Gilead Sciences, Inc.